Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer.
National Cancer Institute (NCI)
cervical cancer
radiopharmaceutical
targeted radioisotope therapy
uterine cervix cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
04
2019
accepted:
10
06
2019
entrez:
13
7
2019
pubmed:
13
7
2019
medline:
13
7
2019
Statut:
epublish
Résumé
Uterine cervix cancers pose therapeutic challenges because of an overactive ribonucleotide reductase, which provides on-demand deoxyribonucleotides for DNA replication or for a DNA damage repair response. Ribonucleotide reductase overactivity bestows cancer cell resistance to the effects of radiotherapy and chemotherapy used to treat disease; but nevertheless, this same biologic overexpression provides opportune vulnerabilities relatively specific to uterine cervix cancers for new therapeutic strategies to take advantage. The discovery of human epidermal growth factor receptor 2 (
Identifiants
pubmed: 31297338
doi: 10.3389/fonc.2019.00560
pmc: PMC6607970
doi:
Types de publication
Journal Article
Langues
eng
Pagination
560Références
N Engl J Med. 1999 Apr 15;340(15):1154-61
pubmed: 10202166
J Clin Oncol. 1999 May;17(5):1339-48
pubmed: 10334517
Nature. 2000 Mar 2;404(6773):42-9
pubmed: 10716435
J Biol Chem. 2000 Jun 9;275(23):17747-53
pubmed: 10747958
Am J Roentgenol Radium Ther Nucl Med. 1975 Jan;123(1):91-9
pubmed: 1119664
Cancer. 1976 Jul;38(1 SUPPL):596-602
pubmed: 1277111
Gynecol Oncol. 2003 Jun;89(3):343-53
pubmed: 12798694
Cancer Res. 1977 Dec;37(12):4389-94
pubmed: 144560
J Clin Oncol. 2004 Mar 1;22(5):872-80
pubmed: 14990643
BMC Cancer. 2004 Sep 01;4:59
pubmed: 15341668
J Biol Chem. 2006 Mar 24;281(12):7834-41
pubmed: 16436374
Philos Trans R Soc Lond B Biol Sci. 2006 Aug 29;361(1472):1351-64
pubmed: 16873123
J Clin Oncol. 2007 Jul 1;25(19):2804-10
pubmed: 17502627
Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14324-9
pubmed: 17726094
Am J Obstet Gynecol. 2007 Nov;197(5):503.e1-6
pubmed: 17980189
Oncology. 2009;76(2):133-41
pubmed: 19174612
Radiat Res. 2009 Dec;172(6):666-76
pubmed: 19929413
Clin Cancer Res. 2010 Feb 15;16(4):1298-306
pubmed: 20145183
J Clin Oncol. 2010 Aug 1;28(22):3562-9
pubmed: 20606083
J Clin Oncol. 2010 Sep 1;28(25):3965-72
pubmed: 20679611
Radiat Res. 2010 Nov;174(5):574-81
pubmed: 20954859
Radiat Res. 2011 Oct;176(4):425-33
pubmed: 21756082
Int J Gynecol Cancer. 2011 Aug;21(6):1117-23
pubmed: 21792015
J Inorg Biochem. 2011 Nov;105(11):1422-31
pubmed: 21955844
Int J Gynecol Cancer. 2012 Nov;22(9):1463-9
pubmed: 23051959
Int J Gynecol Cancer. 2013 May;23(4):615-21
pubmed: 23552804
Gynecol Oncol. 2013 Jul;130(1):75-80
pubmed: 23603372
Int J Gynaecol Obstet. 2014 May;125(2):97-8
pubmed: 24630859
Gynecol Obstet (Sunnyvale). 2011 Dec 10;Suppl 4:001
pubmed: 25392744
Gynecol Oncol. 1989 Dec;35(3):314-20
pubmed: 2599466
Oncotarget. 2015 Nov 3;6(34):36219-30
pubmed: 26435481
Gynecol Oncol. 2016 Dec;143(3):611-616
pubmed: 27697287
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
Front Oncol. 2018 Apr 10;8:102
pubmed: 29692980
Am Soc Clin Oncol Educ Book. 2018 May 23;38:488-494
pubmed: 30231365
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36
pubmed: 30306584
Gynecol Oncol. 2019 Jan;152(1):87-93
pubmed: 30389105
Front Oncol. 2019 Feb 25;9:97
pubmed: 30859091
Biochemistry. 1993 Nov 2;32(43):11569-74
pubmed: 8218224
Lancet. 1997 Aug 23;350(9077):535-40
pubmed: 9284774
Cancer Res. 1998 May 15;58(10):2245-52
pubmed: 9605773